We show that intravitreal Bevacizumab treatment for macular edema induced by BRVO leads to a fast and significant improvement of visual acuity and a concurrent decrease of CRT. Similar results were ...
Leuven, April 23, 2015 - ThromboGenics NV (Euronext Brussels:THR), an integrated biopharmaceutical company focused on developing and commercializing innovative medicines for the treatment of ...
– If approved by the FDA, RVO would be Vabysmo’s third indication in addition to wet age-related macular degeneration (AMD) and diabetic macular edema (DME) – – Vabysmo is the first and only treatment ...
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Genentech, Inc., a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) has approved ...
– Additional U.S. label update across indications includes information on rare post-marketing reports of retinal vasculitis and/or retinal vascular occlusion; reporting rate is in line with other ...
DelveInsight’s “Retinal Vein Occlusion Pipeline Insight 2025” report provides comprehensive insights about 15+ companies and 15+ pipeline drugs in the Retinal Vein Occlusion pipeline landscape. It ...
Background: Branch retinal vein occlusion is a frequent cause of visual loss with currently insufficient treatment options. We evaluate the effect of Bevacizumab (Avastin ®) treatment in patients with ...
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) announced today that the U.S. Food and Drug Administration (FDA) has approved Vabysmo ...
– RVO is the third indication for Vabysmo, in addition to wet, or neovascular, age-related macular degeneration and diabetic macular edema – – Approval is based on two Phase III studies demonstrating ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results